Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Atrium Therapeutics, Inc.NASDAQ: RNA
Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue (non-current) of $36.35M in Q1 FY2026
Q1 FY2026 deferred revenue (non-current) was $36.35M.
Context
- Deferred revenue (non-current) amounted to 12.4% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 28.69M USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.69M | — |
Deferred Revenue (Non-current) vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Deferred Revenue (Non-current) figures are available to compare.
Balance Sheet
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.